Articles
Policymakers are once again focusing attention on proposals to lower prescription drug costs. Read More ›
As biosimilars are being used more and more in cancer treatment, it is increasingly important that navigators and financial advocates be familiar not only with how they work but also how patients with cancer should go about paying for them, according to Angie Santiago, AA, CRCS-I, lead financial advocate at the Sidney Kimmel Cancer Center/Jefferson Health. Read More ›
By William King
During the 2021 European Society for Medical Oncology virtual meeting, 5-year follow-up data from a clinial trial showed comparable results related to cardiac safety and long-term efficacy between trastuzumab (Herceptin) and the biosimilar trastuzumab-dttb (SB3; Ontruzant) in patients with HER2-positive, early or locally advanced breast cancer. Read More ›
By Anne Rowe
Results from a phase 3 clinical trial showed equivalence between the bevacizumab biosimilar, BCD-021, and the reference product, bevacizumab (Avastin), in terms of overall response rate (ORR) in patients with stage IIIB or IV nonsquamous non–small-cell lung cancer. Read More ›
Febrile neutropenia (FN) is a serious side effect of many cancer treatments and can lead to severe infection and sepsis with potentially fatal consequences. Read More ›
Biosimilars are poised to bring significant cost-savings opportunities in oncology, while maintaining high-quality patient care. Read More ›
Cancer remains one of the costliest diseases to treat in the United States. Read More ›
Cancer remains one of the costliest diseases to treat in the United States. Read More ›
On August 20, 2021, a group of 16 organizations representing patients, consumers, providers, and taxpayers published an open letter to officials from the Centers for Medicare & Medicaid Services and the Department of Health and Human Services asking them to consider enacting a zero copay policy for Medicare Part B patients, a move the groups said would improve access to biosimilars and save seniors in Medicare as much as $3 billion in out-of-pocket costs. Read More ›
Approximately 13% of patients with lung adenocarcinoma harbor the KRAS p.G12C mutation, which is associated with poor clinical outcomes. Read More ›